Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Chemical & Pharmaceutical Bulletin|September 1, 1992
Synthesis of a dibenz[b,e]oxepin-bovine serum albumin conjugate for radioimmunoassay of KW-4679 ((Z)-11-[3-(dimethylamino)propylidene]-6,11- dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride)E Ohshima, H Sato, H Obase, et al.
Arzneimittel-Forschung|December 1, 1991
Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrateA Karasawa, M Kawakage, S Shirakura, et al.
Japanese Journal of Pharmacology|July 1, 1992
Effects of KW-3635, a novel dibenzoxepin derivative of a selective thromboxane A2 antagonist, on human, guinea pig and rat plateletsI Miki, N Kishibayashi, H Nonaka, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1983
Natural 25,26-dihydroxyvitamin D3 is an epimeric mixtureN Ikekawa, N Koizumi, E Ohshima, et al.
Journal of Neurochemistry|February 7, 2001
Endogenously released DOPA is a causal factor for glutamate release and resultant delayed neuronal cell death by transient ischemia in rat striataN Furukawa, N Arai, Y Goshima, et al.
Journal of Medicinal Chemistry|September 4, 1992
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1E Ohshima, H Takami, H Sato, et al.
European Journal of Pharmacology|May 21, 1998
Unique binding pocket for KW-4679 in the histamine H1 receptorH Nonaka, S Otaki, E Ohshima, et al.
Life Sciences|April 21, 1999
Some interactions of L-DOPA and its related compounds with glutamate receptorsT Miyamae, Y Goshima, M Shimizu, et al.
Neuroscience Letters|February 13, 2001
DOPA cyclohexyl ester, a competitive DOPA antagonist, protects glutamate release and resultant delayed neuron death by transient ischemia in hippocampus CA1 of conscious ratsN Arai, N Furukawa, T Miyamae, et al.
Journal of Medicinal Chemistry|May 28, 1993
Dibenzoxepin derivatives: thromboxane A2 synthase inhibition and thromboxane A2 receptor antagonism combined in one moleculeE Ohshima, H Sato, H Obase, et al.
Pageof 2